In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

GREENVILLE, S.C. (WSPA) – September is Prostate Cancer Awareness Month, and doctors emphasize that early detection can save lives. Despite its prevalence, many misconceptions about the disease persist ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

A recent abstract published in Nature Communications outlines a new, easy-to-use tool that could help guide early treatment discussions for people with mHSPC. In a nutshell, the innovative system ...

Researchers analyzed individual patient data from 13 randomized phase III trials, and learned the benefit of androgen deprivation therapy (ADT) increases in a non-linear fashion. While longer ADT ...